Statement

Sl. No.	Name of the bulk drug	Unit	Previous Price	Revised Price	Date
1.	Ampicillin Trihydrate	Kg.	1859.00	2054.00	6-9-88
			2054.00	1925.00	21-3-89
			1925.00	2216.00	9-10-91
			2216.00	2516.00	13-4-92
			2516.00	3098.00	27-7-92
2.	Ampicillin Anhydrous	Kg.	2368.00	2790.00	6-9-88
			2790.00	2631.00	21-3-89
			2631.00	3341.00	24-2-92
			3341.00	3599.00	27-7-92
3.	Amoxycillin Trihydrate	Kg.	2495.00	2865.00	6-9-88
			2865.00	2660.00	21-3-89
			2660.00	2093.00	11-2-91
			2093.00	2649.00	14-10-91
			2649.00	2922.00	13-3-92
			2922.00	3216.00	27-7-92
4.	Doxycycline	Kg.	5486.00	4968.00	9-8-80
			4968.00	5416.00	20-8-92

Amount Overcharged by M/s. Lyka Labs.

1610. SHRI ANANT RAM JAISWAL: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 734 given in Rajya Sabha on the 16th July, 1992 and state :

(a) what is the amount overcharged by M/s. Lyka Labs, on the Flucort range of formulations between 9th March and 13th July, 1990 and whether the total recoverable amount upto this period has been worked out;

(b) what is the magnitude of over charging and pack-wise earlier and revised prices of the formulations w.e.f. 12th October, 1990;

(c) when parawise comments were sent on the writ to the Government advocate in September, 1990; and

(d) what are the reasons for delay in filing of counter-affidavit and what steps have been taken to fix responsibility for the delay ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) : (a) and (b) The tentative liability into DPEA of M/s. Lyka Labs, in respect of Fluocinolone Acetonide has been worked out as Rs. 678.73 lakhs for the period from 1-4-1979 to 25-8-1987 on the basis of data furnished by the company regarding quantity *ot* bulk drng *consumed in*

their formulations. The data regarding production, sales and stocks of various packs of formulation based on this bulk drug has not been provided by the Comnpany. The company has been reminded to submit the data for the period after 25th August, 1987 for computing their liability for overcharginig the formulation places. After getting these details the liability for the period after, 25th August, 1987 would be worked out.

(c) and (d) The Parawise comments on the writ petition filed by M/s. Lyka Labs, were sent to the Central Govern ment Advocate in September 1990, and the counter affidavit was filed in this case by the Government in February, 1992. The delay occured in filing coun ter affidavits due *to* change of Central Government Advocate at Bombay High Court. The matter was constantly pur sued by this Department.

Obligatory Forms /Data under DPCO, 1981

1611. SHRIMATI KAILASHPATI : Will the PRIME MINISTER be pleased to state :

(a) what are the details of Forms/ data which are obligatory for Drug Industry to submit under DPCO, 1987 and Drug Policy, 1986;

(b) what are the aspects which his Ministry are monitoring;

(c) whether it is a fact that production of bulk drugs have declined, profitability has gone up, no fresh investment is being made and imports of drugs, formulations and intermediates have gone up;

(d) what was the production of each drug by M/s. Reptakos Brett, Boots, Ral lies synbiotics *Abbott,Glaxo,* Infers; Roche, Pfizor, Roussel, Fulford, Merind, Hoechst, Rohone Poulanc, Sandoz during last three years, yearwise and stage of manufacture of each;

(e) what are the names *ot* intermediates, bulk drugs and formulations being imported by each and what was the import of each; and

(f) what are the names of formulations for which these companies increased the prices after 1987 and what was its earlier and present price ?

THE MINISTER OF STATE 'N THE MINISTRY OF CHEMICALS AND FER-TILIZERS (SHRI CHINTA MOHAN) :

(a) and (b) These details have been provided in the DPCO, 1987 notified vide Gazette Notification No. S. O. 794 (E) dated 26-8-1987, as amended from time to time and monitoring to the extent possible is being done.

(c) As- per the Hand book of company-wise production of monitored bulk drugs (1986-87 to 1990-91) it cannot be infer red that the production of bulk drugs has shown general decline. On the basis of Form 6, received from the companies, in general, has gone up. It is not correct that no fresh investment is being made. Though total imports of drug intermedia tes, drugs and formulations has been go ing up, part of this is used for expert production and exports have also increas ed. As a result, industry has emerged as a net foreign exchange earner during the last 3 years.

(d) To the extent available, infown:_tion is given in the Statement enclosed. *(See* below).

(e) and (f) Time and effort involved in compiling this Voluminous information would not be commensurate with the results likely to be achieved.